Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg (lung cancer)

Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg in unresectable advanced or recurrent lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031230346

Enrollment

100

Registered

2023-09-14

Start date

2023-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 (ERBB2) -mutant, unresectable, advanced or recurrent NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all the following criteria at the time of registration: (1) Enhertu-naive patients with HER2 (ERBB2) -mutant, unresectable, advanced or recurrent NSCLC; (2) patients previously untreated with investigational formulations of Enhertu; (3) patients who have started receiving Enhertu within the contract period (contract period based on the institution-specific agreement); (4) patients who have started receiving Enhertu within the registration period of the survey; and (5) patients who have provided written consent to participate in the survey.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
ILD expression based on the judgement result of ILD outside judgment Committee	—

Secondary

Measure	Time frame
occurrence of ILD as reported by physicians	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-362251059

Outcome results